melanocortin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The trial judge did not accept this defence, noting that comments such as Galloway being guilty of "treason", "in Saddam's pay", and being "Saddam's little helper" caused him [the judge] to conclude that "the newspaper was not neutral but both embraced the allegations with relish and fervour and went on to embellish them"; additionally, the judge ruled, Galloway had not been given a fair or reasonable opportunity to make inquiries or meaningful comment upon the documents before they were published.
=== Asexual === All known cnidarians can reproduce asexually by various means, in addition to regenerating after being fragmented. Hydrozoan polyps only bud, while the medusae of some hydrozoans can divide down the middle. Scyphozoan polyps can both bud and split down the middle. In addition to both of these methods, Anthozoa can split horizontally just above the base. Asexual reproduction makes the daughter cnidarian a clone of the adult. The ability of cnidarians to asexually reproduce ensures a greater number of mature medusa that can mature to reproduce sexually.
Iraqi authorities announce that the US transferred the diplomatic and logistics hub at Baghdad International Airport to Iraq prior to the withdrawal of American soldiers from the country. Chinese leader Xi Jinping meets Trump at the White House during his first visit to Washington in a decade. The two leaders discuss trade, artificial intelligence, Taiwan and international conflicts, and agree to extend the existing US–China trade truce by two months. September 25 – Cities and states across the United States, including Lexington, Nashville, New Orleans, and Portland, hold commemorations honoring former American country singer Dolly Parton including the 9 to 5 song one month after her death. California becomes the first U.S. state to designate September 25 as Dolly Parton Day. September 26 A powerful nor'easter strikes the northeast United States. A New York City Housing Authority employee is killed by a falling tree in Brooklyn. Trump rejects Iran's seven-day ceasefire proposal over nuclear concerns. The Wall Street Journal reports that he privately expects U.S. bombing to resume after the midterm elections in November, although the scale remains undecided amid dwindling munitions stockpiles. September 27 – Trump says that he still expected more talks to resume with Iran during the week. Trump claims that Iran "wanted to make a deal," but they "overplayed their hand" by offering conditions that the US "would have maybe agreed to a year ago." September 28 SpaceX's Starship achieves orbit for the first time, and deploys 26 "next generation" Starlink V3 satellites.
== Production == Ron Shapiro – executive producer, A&R James Hunter – A&R Patrick Leonard – producer arrangements Duncan Sheik – co-producer arrangements Michele Arifty – personal assistant to Patrick Leonard Lisa Marie – representative Suzanne Ybarra – representative Moir/Marie Entertainment – representation company Jim Goodkind – legal affairs Loeb & Loeb – legal affairs Katrina Leigh – project coordinator Lynn Kowalewski – art direction Allen Hori – design Philippe McClelland – photography Technical credits
Sources: en.wikipedia.org
Powstanie Wielkopolskie, [in:] J.Pajewski, Odbudowa państwa polskiego 1914–1918, Warszawa 1985, Janusz Pajewski, Znaczenia Powstania Wielkopolskiego dla odbudowy Państwa Polskiego w 1918 r., Zeszyty Naukowe UAM, Historia 1970, t.10 S. Rybka, Zerwane pęta. Wspomnienia z dni rewolucji niemieckiej i powstania polskiego 1918-1919, Poznań 1919 A. Rzepecki, Powstanie grudniowe w Wielkopolsce. 27 XII 1918, Poznań 1919 Z. Wieliczka, Wielkopolska w Prusy w dobie powstania 1918/1919, Poznań 1932 Z. Wroniak, Paderewski w Poznaniu, Kronika Miasta Poznania 1959, nr 4 H. Zieliński, Rola powstania wielkopolskiego oraz powstań śląskich w walce o zjednoczenie ziem zachodnich z Polską; (1918–1921), [in:] Droga przez Półwiecze. Dietrich Vogt: Der großpolnische Aufstand 1918/1919: Bericht, Erinnerungen, Dokumente. Marburg 1980 (J.-G.-Herder-Institut) ISBN 3-87969-147-9 Richard Blanke, Orphans of Versailles. The Germans in Western Poland 1918–1939, Lexington, KY., 1993 (presents somehow pro-German vision of the events)
=== Frequency multiplier === In 2009, researchers built experimental graphene frequency multipliers that take an incoming signal of a certain frequency and output a signal at a multiple of that frequency.
The affinity, given as the dissociation constant (Kd), between a TCR and a pMHC was determined by surface plasmon resonance (SPR) to be in the range of 1–100 μM, with an association rate (kon) of 1000 -10000 M−1 s−1 and a dissociation rate (koff) of 0.01 -0.1 s−1. In comparison, cytokines have an affinity of KD = 10–600 pM to their receptor. It has been shown that even a single amino acid change in the presented peptide that affects the affinity of the pMHC to the TCR reduces the T-cell response and cannot be compensated by a higher pMHC concentration. A negative correlation between the dissociation rate of the pMHC-TCR complex and the strength of the T-cell response has been observed. That means, pMHC that bind the TCR for a longer time initiate a stronger activation of the T cell. Furthermore, T cells are highly sensitive; interaction with a single pMHC is enough to trigger activation. T cells move on quickly from antigens that do not trigger responses, rapidly scanning pMHC on an antigen-presenting cell (APC) to increase the chance of finding a specific pMHC. On average, a T cell encounters 20 APCs per hour. Different models for the molecular mechanisms that underlie this highly specific and highly sensitive process of antigen discrimination have been proposed. The occupational model simply suggests that the TCR response is proportional to the number of pMHC bound to the receptor. Given this model, a shorter lifetime of a peptide can be compensated by higher concentration such that the maximum response of the T cell stays the same.
ISBN 978-1-119-54212-4. OCLC 1083261548. Stvrtinová V, Jakubovský J, Hulín I (1995). Pathophysiology: Principles of Disease. Computing Centre, Slovak Academy of Sciences: Academic Electronic Press. Swartz, Mark H. (2010). Textbook of Physical Diagnosis: History and Examination (6th ed.). Saunders/Elsevier. ISBN 978-1-4160-6203-5. Concise Oxford Companion to the English Language 1998 entries on classical compound and combining form Taber, Clarence Wilbur; Thomas, Clayton L.; Venes, Donald (2001). Taber's cyclopedic medical dictionary (Ed. 19, illustrated in full color ed.). Philadelphia: F.A.Davis Co. ISBN 0-8036-0655-9. ISSN 1065-1357. Waquet, Françoise (2001). Latin, or the Empire of a Sign: From the Sixteenth to the Twentieth Centuries. Translated by John Howe. Verso. ISBN 1859844022.
According to the Endocrine Society, there is "growing evidence suggesting that obesity is a disorder of the energy homeostasis system, rather than simply arising from the passive accumulation of excess weight" and that "obesity pathogenesis involves two related but distinct processes: (1) sustained positive energy balance (energy [caloric] intake > energy expenditure) and (2) resetting of the body weight "set point" at an increased value." In other words, the fundamental cause of obesity is consuming more calories than are used by the body, and the body adapting to a heavier weight as the standard for the individual.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.